Log In
BCIQ
Print this Print this
 

PVS-10200

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionTissue-engineered allogeneic endothelial cells
Molecular Target Not applicable
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Organ/tissue engineering
Latest Stage of DevelopmentPhase I/II
Standard IndicationRestenosis
Indication DetailsPrevent restenosis in peripheral arterial disease (PAD) patients undergoing angioplasty or a stent procedure; Treat interventions for peripheral arterial disease (PAD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$200.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/16/2012

$200.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today